{"doi":"10.17615/tde0-ye85","title":"ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.","abstract":"Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant Klebsiella pneumoniae isolates, predominantly K. pneumoniae carbapenemase producing, were susceptible to ceftibuten-ledaborbactam (ledaborbactam tested at a fixed concentration of 4 mg/L) compared to 4.5% and 30.5%, respectively, to ceftibuten alone.","journal":"UNC Libraries","year":2025,"id":581125,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9535,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":32929,"name":"Vance G. Fowler","orcid":"0000-0002-8048-0897","position":1,"is_corresponding":false},{"id":685221,"name":"Daniel D. Rhoads","orcid":"0000-0002-7636-5191","position":2,"is_corresponding":false},{"id":232749,"name":"Andrea M. Hujer","orcid":"0009-0001-3543-1826","position":3,"is_corresponding":false},{"id":624373,"name":"Robert A Bonomo","orcid":null,"position":4,"is_corresponding":false},{"id":384425,"name":"Christopher R. Bethel","orcid":null,"position":5,"is_corresponding":false},{"id":491853,"name":"Michael R. Jacobs","orcid":"0000-0002-4235-7855","position":6,"is_corresponding":false},{"id":1238987,"name":"Ayman M. Abdelhamed","orcid":null,"position":7,"is_corresponding":false},{"id":232741,"name":"David van Duin","orcid":"0000-0003-4784-3227","position":8,"is_corresponding":false},{"id":1218567,"name":"Tsuyoshi Uehara","orcid":"0000-0001-6994-4286","position":9,"is_corresponding":false},{"id":234484,"name":"Kristine M. Hujer","orcid":null,"position":10,"is_corresponding":false},{"id":270505,"name":"Krisztina M. Papp‐Wallace","orcid":"0000-0002-9976-7898","position":11,"is_corresponding":false},{"id":887202,"name":"David A. Six","orcid":"0000-0002-9013-1711","position":12,"is_corresponding":false},{"id":666474,"name":"Greg Moeck","orcid":"0000-0001-7827-7227","position":13,"is_corresponding":false},{"id":232756,"name":"Robin Patel","orcid":"0000-0001-6344-4141","position":14,"is_corresponding":false},{"id":619530,"name":"Caryn E. Good","orcid":null,"position":15,"is_corresponding":false},{"id":270506,"name":"Andrew R Mack","orcid":"0000-0002-0131-7996","position":16,"is_corresponding":false},{"id":594792,"name":"Steven H. Marshall","orcid":"0009-0003-1811-2633","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:58:47.357782Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}